1. Home
  2. BYFC vs CRDF Comparison

BYFC vs CRDF Comparison

Compare BYFC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Broadway Financial Corporation

BYFC

Broadway Financial Corporation

N/A

Current Price

$11.66

Market Cap

90.3M

Sector

Finance

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$0.89

Market Cap

82.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BYFC
CRDF
Founded
1946
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.3M
82.5M
IPO Year
2013
2012

Fundamental Metrics

Financial Performance
Metric
BYFC
CRDF
Price
$11.66
$0.89
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $5.81
AVG Volume (30 Days)
1.7K
★ 442.1K
Earning Date
07-28-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.37
EPS
★ 0.07
N/A
Revenue
$184,000.00
★ $365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8.70
P/E Ratio
$162.43
★ N/A
Revenue Growth
18.71
★ 49.61
52 Week Low
$5.51
$0.76
52 Week High
$12.35
$3.31

Technical Indicators

Market Signals
Indicator
BYFC
CRDF
Relative Strength Index (RSI) 39.55 30.24
Support Level $9.29 $0.88
Resistance Level $12.27 $1.13
Average True Range (ATR) 0.14 0.06
MACD -0.06 -0.03
Stochastic Oscillator 0.00 4.34

Price Performance

Historical Comparison
BYFC
CRDF

About BYFC Broadway Financial Corporation

Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank offers a variety of commercial real estate loan products, services, and depository accounts that support investments in affordable housing, small businesses, and nonprofit community facilities located within low-to-moderate income neighborhoods.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Share on Social Networks: